Abstract: An object of the present invention is to provide an option of non-reducing saccharide by providing a novel non-reducing saccharide composed of glucose as constituents and to provide a novel enzyme forming the non-reducing saccharide, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the non-reducing saccharide, and uses thereof. The present invention solves the above object by providing a novel cyclic saccharide having a structure of cyclo{?6)-?-D-glucopyranosyl-(1?4)-?-D-glucopyranosyl-(1?6)-?-D-glucopyranosyl-(1?4)-?-D-glucopyranosyl-(1?6}, cyclic maltosylmaltose, novel cyclic maltosylmaltose-forming enzyme, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the cyclic maltosylmaltose or a saccharide composition comprising the same, and uses thereof.

Abstract: Compounds and compositions for the delivery of bisphosphonates are provided. Methods of preparation, administration and treatment are provided as well.

Abstract: Compounds of formula (I) wherein A is N or N+—O?; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Abstract: Dihydrate and anhydrous crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2?,3?-e] [1,4]diazepin-6-one.

Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.

Abstract: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.

Abstract: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: The use of selective imidazoline receptor agonists, such as moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847 and BU-98008, and their physiologically compatible acid addition salts in pharmaceutical preparations for the treatment and/or inhibition of functional disorders and/or diseases in larger mammals or humans which require inhibition or reduction of the activity of proteins which regulate the intracellular pH value and which belong to the superfamily of bicarbonate transporters, in particular the treatment or inhibition of clinical conditions of bones which are caused by an undesirable amount of bone resorption, such as osteoporosis; of diseases of the gastrointestinal tract, such as gastric ulcers; and of neuronal and/or neuropsychiatric diseases associated with a pathologically altered (especially increased) neuronal activity, such as depression, Alzheimer's disease, eating disorders and schizophrenia.

Abstract: The invention relates to a crystalline micronisate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.

Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: The present invention relates to compounds of the Formula: wherein R1 to R6, X, Z and A are as defined. These compounds have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the present Formula.

Abstract: Obtaining the crystal of 4,6-dimethyl-4?-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca2+ release-activated Ca2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions.

Abstract: The invention relates to novel fungicidallly active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide of the formula and the active compounds listed in the disclosure.

Abstract: Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

Abstract: The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.

Abstract: The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: A compound having Formula I wherein one of R1 and R2 is a group of the formula wherein R4 is selected from H and hydrocarbyl, R5 is a hydrocarbyl group and L is an optional linker group, or R1 and R2 together form a ring substituted with the group wherein R3 is H or a substituent, and wherein X is selected from S, O, NR6 and C(R7)(R8), wherein R6 is selected from H and hydrocarbyl groups, wherein each of R7 and R8 are independently selected from H and hydrocarbyl groups.

Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.

Abstract: In one embodiment, the present application relates to a process of making a compound of formula I. and to certain intermediate compounds that are made within the process of making the compound of formula I.

Abstract: The present invention discloses a dibenzocycloheptene compound represented by the formula (I): wherein R1: hydrogen atom, halogen atom, etc., R2: hydrogen atom, halogen atom, etc., A: 5-membered or 6-membered heteroaromatic ring group containing 1 to 3 hetero atom(s) selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and the heteroaromatic ring group, etc. may have halogen atom, nitrogen atom, etc. as substituent(s), B: formula; —CH?CH—, formula; —CH2O—, etc., Y: C1-C10 alkylene group which may have halogen atom, etc. as substituent(s), etc., Z: carboxyl group which may be protected, etc.

Abstract: The present invention provides a stabilized pharmaceutical preparation of a 4-amino-3-substituted-butanoic acid derivative which can be obtained by incorporating an amino acid as a stabilizer.

Abstract: A compound of formula (I) wherein T represents O, S or NR and wherein R represents a H, a C1-6alkyl group or a phenyl C1-6alkyl group and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and and pharmaceutical compositions containing them

Abstract: The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

Abstract: The present invention provides a composition for film formation which can form a porous film that excels in dielectric properties, adhesion, film consistency and mechanical strength, and that is easily thinned; a porous film and a method for forming the same, and a high-performing and highly reliable semiconductor device which contains the porous film inside. More specifically, the composition for forming a porous film comprises a solution containing an amorphous polymer which is obtained by hydrolyzing and condensing at least one silane compound expressed by the general formula (R1)nSi(OR2)4?n, and a zeolite sol which is formed by using a quaternary ammonium hydroxide. The method for forming a porous film comprises a coating step for coating the composition for forming a porous film; a subsequent drying step; and a porousness forming step.

Abstract: The invention provides nanoparticles comprising one or more redox-active species, methods of making such nanoparticles, and methods for using such nanoparticles, for example, as diagnostic agents for the detection of various analytes.

Abstract: In accordance with the present invention, there are provided novel thermosetting resin compositions which do not require solvent to provide a system having suitable viscosity for convenient handling. Invention compositions have the benefit of undergoing rapid cure. The resulting thermosets are stable to elevated temperatures, are highly flexible, have low moisture uptake and are consequently useful in a variety of applications, e.g., in adhesive applications since they display good adhesion to both the substrate and the device attached thereto.

Abstract: A fibrous base material giving a wet frictional material used for clutch, differential gear, brake, etc. of cars, industrial machines, etc. having an excellent durability where plastic deformation of fiber and deterioration by acidic decomposition products of lubricant additives do not take place is provided. A fibrous base material for wet frictional materials which comprises a fiber component, a friction adjusting material and a filler, said fiber component containing 5 to 50% by weight of a homoacrylonitrile fiber where modulus of elasticity at 180° C. is not less than 10 cN/dtex and shrinking rate at 200° C. is within 5% and/or a homoacrylonitrile fiber in a pulp form prepared by fibrillation of said homoacrylonitrile fiber.

Abstract: The invention relates to a straight-oil finishing composition comprising (A) 100 parts by weight of a polydimethylsiloxane oil or liquid paraffin having a viscosity of 3 to 70 mm2/s at 25 centigrade temperature; and (B) 0.5 to 100 parts by weight of an organopolysiloxane resin, which contains silanol groups and silicon-bonded alkoxy groups and wherein 20 mole % or more of all siloxane units are siloxane units represented by formula C3H7SiO3/2. This composition is useful for treating fiber yarn.

Abstract: Disclosed herein is an electrically conductive precursor composition comprising an organic polymer precursor; a single wall nanotube composition, wherein the single wall nanotube composition contains at least 0.1 wt % of production related impurities; and an optional nanosized conductive filler. A conductive composition comprises an organic polymer; a single wall nanotube composition, wherein the single wall nanotube composition contains at least 0.1 wt % of production related impurities; and a nanosized conductive filler.

Abstract: A freeform fabrication system preferably includes low-density particles, a cationic polyelectrolyte component, an anionic polyelectrolyte component, and a polar solvent-based binder capable of stimulating a reaction between the cationic polyelectrolyte component and the anionic polyelectrolyte component to form a low-density particle-bound polyelectrolyte complex.

Abstract: Aqueous-form additive systems, and methods of blending the same with a matrix resin, are disclosed whereby acrylic-based impact modifier compositions, butadiene-based impact modifier compositions and acrylic-based processing aids are used in aqueous form without the need for isolation to the traditional powder-form. The aqueous additive systems of the present invention provide a means for the design of novel additive compositions. The aqueous additive systems of the present invention also provide a great degree of flexibility in preparation of matrix resin blends and formulations. Additionally, the aqueous additive systems of the present invention allow for the reduced cost of manufacturing additives and reduced cost in blending matrix resin formulations.

Abstract: A composition formed from (a) a polyester and polycarbonate blend; (b) an organopolysiloxane-polycarbonate block copolymer; (c) an acrylic core shell impact modifier; (d) titanium dioxide and (e) a flame retarding amount of a halogenated flame retardant has properties useful as a weatherable molding composition. It can suitably be used in articles such as encloses for electronic equipment such as communication devices.

Abstract: This invention relates to ink-receptive coating compositions and to articles containing a layer formed from such coating compositions. In one embodiment, the articles comprise a polymer film substrate and an ink-receptive layer on the upper surface of the polymer film substrate. In another embodiment, the article also comprises an adhesive layer on the bottom surface of the polymer film substrate. The articles may have a print image on the upper surface of the ink-receptive layer, and such print images exhibit improved performance when exposed to extreme environments such as high temperatures, water, solvents and abrasion.

Abstract: The present invention is directed to silicone formulations which are capable of being rapidly cured to tough elastomeric materials through exposure to UV radiation, and optionally through exposure to moisture as well. The cured products demonstrate high resistance to flammability and combustibility.

Abstract: An organopolysiloxane composition which contains from 0.01% to less than 0.5% by weight of a sulfidable metal powder is provided. When a silver-containing precision electronic part is encapsulated or sealed with the cured composition, the metal powder in the cured composition is sulfided with sulfur-containing gas, thereby preventing or retarding the corrosion of the encapsulated or sealed electronic part with the sulfur-containing gas.

Abstract: An extremely durable, stable and fast-curing elastomeric composition suitable for coating all types of architectural glass is disclosed.

Abstract: A method for preparing a thermoplastic composition containing an antistatic agent is described. The antistatic agent is a phosphonium sulfonate salt of generic formula (1) wherein each X is independently a halogen or hydrogen, provided that the molar ratio of halogen to hydrogen is greater than about 0.90; p is 0 or 1 and q and r are integers of 0 to about 7 provided that q+r is less than 8 and that if p is not zero then r is greater than zero; and each R is the same or different hydrocarbon radical containing 1 to about 18 carbon atoms. The phosphonium sulfonate salt is prepared by a method that includes combining in an aqueous medium a compound of generic formula (2) wherein M is Li or Na, and X, q, p, and r are as defined above, with a stoichiometric excess of a compound of the generic formula (3) (R)4P-Z??(3) wherein Z is a halogen and R is as defined above; and separating the product of formula (1) from the medium. The phosphonium sulfonate salt is then combined with a thermoplastic resin.

Abstract: The present invention provides a novel acrylic block copolymer rich in flexibility and excellent in mechanical strength, moldability, oil resistance, heat resistance, thermal decomposition resistance, weather resistance, and compression set, and further rich in reactivity. The present invention also provides compositions, seal products, and automobile, electric, and electronic parts, all of which include the acrylic block copolymer. The acrylic block copolymer includes a methacrylic polymer block (a) and an acrylic polymer block (b), at least one of the polymer blocks containing, in its main chain, at least one acid anhydride group (c) represented by formula (1): (wherein R1s each represent hydrogen or a methyl group and may be the same or different, n represents an integer of 0 to 3, and m represents an integer of 0 or 1).

Abstract: The present invention relates to an acrylic pressure sensitive adhesive composition containing organic functional groups of urethane and pyridine, more precisely an acrylic pressure sensitive adhesive composition which has excellent removability owing to its low initial peel strength on glass and excellent long-term durability since the peel strength of the pressure sensitive adhesive composition onto glass is being increased under high temperature and high humidity. The present invention also relates to an acrylic pressure sensitive adhesive composition for a polarizer having excellent adhesive functions and durability, a polarizer and a LCD containing the same.

Abstract: The invention provides polymer blends containing polyhydroxyamide and one or more flammable polymers. The polymer blends are flame retardant and have improved durability and heat stability compared to the flammable polymer portion of the blends. Articles containing the polymer blends are also provided.

Abstract: A polymer blend and a method of making the same are provided. The polymer blend includes an ethylene-propylene (C2-C3) random copolymer and a modifier selected from the group consisting of a metallocene-catalyzed polyethylene-based copolymer, a metallocene-catalyzed polyethylene-based terpolymer, and a syndiotactic polypropylene homopolymer. The polymer blend may also include an organic peroxide for visbreaking the polymer blend. An end use article is made from the foregoing polymer blend. The end use article may be, for example, a film, an injection molded article, a compression molded article, a thermoformed article, and a fiber. The end use article is desirably a film having an Elmendorf tear strength of at least about 300 g/ply in the machine and transverse directions.

Abstract: A biaxially stretched polypropylene film of the present invention has high stiffness in the film longitudinal direction and can be manufactured by a conventional longitudinal-transverse sequential biaxial stretching method, since the biaxially stretched polypropylene film comprises a polypropylene which comprises a polypropylene having controlled specific values of a melt strength (MS) and a melt flow rate (MFR) at 230° C. or consists of a polypropylene having controlled specific values of a melt strength (MS) and a melt flow rate (MFR) at 230° C. and/or a Trouton ratio of the polypropylene is controlled at a specific value, moreover, the biaxially stretched polypropylene film contains regulated longitudinal fibrils.

Abstract: A polyolefin blend comprising: (a) from 30 to 80 weight % of a low molecular weight copolymer comprising from 85 to 100 weight % of ethylene and from 15 to 0 weight % of one or more C4-8 alpha olefins having a density from 0.953 to 0.965 g/cm3 and a melt flow rate (2.16 kg 190° C.) from 0.1 to 20.0 g/10 minutes; and (b) from 70 to 20 weight % of a high molecular weight copolymer comprising from 85 to 99.9 weight % of ethylene and from 15 to 0.1 weight % of one or more C4-8 alpha olefins having a density from 0.915 to 0.940 g/cm3 and a melt flow rate (21.6 kg 190° C.) from 0.05 to 5.0 g/l 0 minutes, said copolymer being prepared with a single site catalyst is useful in the preparation of pipe.

Abstract: An impact copolymer having a flexural modulus (ASTM D-790) of at least about 1,100 MPa; a melt flow rate (ASTM D-1238) of at least about 15 g/10 min; and a maximum load under Dynatup Impact test (ASTM D-3763) of equal to or greater than about 1,700 N at a temperature of less than or equal to about ?40° C. and articles of manufacture from same.

Abstract: To provide a novel crosslinking system of fluorine-containing elastomer giving a crosslinked product particularly having improved mechanical strength and compression set at high temperature. A fluorine-containing rubber composition comprising a fluorine-containing elastomer having carboxyl group and/or alkoxycarbonyl group at an end of a trunk chain and/or branched chain as a crosslinkable group.

Abstract: An article of manufacture made of an isotactic polymer, a cross-linking agent, and an accelerator. The cross-linking agent includes a peroxide and a sulfur. The peroxide has an activity ranging from about 40% to about 100%. The ratio of the accelerator to the sulfur ranges from about 1:4 to about 1:10 depending on the activity, and the ratio of the accelerator to the peroxide ranges from about 1:4 to about 1:10 depending on the activity. The article is formed by mixing the polymer, the cross-linking agent, and the accelerator at high shear rates forming a blend. The blend is heated and sent through an extruder at a temperature less than 140 degrees Celsius for less than one minute. The blend is then inserted into a molding, wherein the formed article comprises a resilience value up to about 50 KJ/m2.

Abstract: A silicone coating material is operative to graft a silicone polymer coating on an ignition wire. The ignition wire includes an insulated conductor with an inner conductive core and an outer insulating jacket layer which has an outer surface. The silicone coating material is applied to the outer surface of the insulating jacket layer and includes a silicone prepolymer, a coupling agent, a catalyst, and a graft initiator. The graft initiator is operative to prepare the outer surface of the insulating jacket to receive by grafting the coating layer including the silicone prepolymer and the coupling agent, and the catalyst is operative to promote grafting by polymerization of the coating layer.

Abstract: Silane-containing polymers are prepared by the polymerization of one or more ethylenically unsaturated monomers in the presence of a silane-containing aldehyde, hemiacetal, or acetal as a regulator, optionally with further regulators as well. The silane-containing regulators produce polymers with superior properties and with improved polymerization parameters as compared to the conventional mercaptosilane regulators.